Shuwen Biotech and Bliss Biopharmaceutical Partner on Companion Diagnostics for Cancer Drugs
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Shuwen Biotech Co. Ltd., an emerging leader in innovative diagnostic products and services announced it has signed a partnership agreement with Bliss Biopharmaceutical Co., Ltd., a biopharmaceutical company engaged in the discovery, development and commercialization of biotherapeutics for unmet medical needs.
Under the agreement, Shuwen will develop companion diagnostics for Bliss’ oncology drug candidates. Shuwen also commits to provide testing services in its CAP-certified central labs for BlissBio’ clinical trials. The terms of the collaboration are undisclosed.
“Companion diagnostics and precision medicine are Shuwen’s major focus. We have partnered with a number of pharmaceutical companies. This collaboration will fuel continued innovation by BlissBio and further demonstrate how Shuwen can deliver value through its strong companion diagnostics development team and its CAP-accredited lab facilities,” said Jay Z. Zhang, Shuwen’s Chairman and Chief Executive Officer.
“We have some of the best-in-class biologics in development. Shuwen provides versatile technologies that may enable the precise selection of the most suitable patients for our drug candidates, thus increasing the competitiveness of our products. We are very happy to work with Shuwen,” commented Dr. Ziping Wei, BlissBio’ Chief Executive Officer.
Under the agreement, Shuwen will develop companion diagnostics for Bliss’ oncology drug candidates. Shuwen also commits to provide testing services in its CAP-certified central labs for BlissBio’ clinical trials. The terms of the collaboration are undisclosed.
“Companion diagnostics and precision medicine are Shuwen’s major focus. We have partnered with a number of pharmaceutical companies. This collaboration will fuel continued innovation by BlissBio and further demonstrate how Shuwen can deliver value through its strong companion diagnostics development team and its CAP-accredited lab facilities,” said Jay Z. Zhang, Shuwen’s Chairman and Chief Executive Officer.
“We have some of the best-in-class biologics in development. Shuwen provides versatile technologies that may enable the precise selection of the most suitable patients for our drug candidates, thus increasing the competitiveness of our products. We are very happy to work with Shuwen,” commented Dr. Ziping Wei, BlissBio’ Chief Executive Officer.
